Literature DB >> 18951762

CD40 on NOD CD4 T cells contributes to their activation and pathogenicity.

Rocky L Baker1, David H Wagner, Kathryn Haskins.   

Abstract

Our goals in this study were to investigate conditions under which T cells from NOD mice express CD40 and to determine how CD40 on autoreactive CD4 T cells contributes to their pathogenicity in T1D. Using CD40-positive diabetogenic T cell clones and CD4 T cells from NOD mice, we examined expression of CD40 upon activation through the TCR and costimulation through either CD28 or CD40. Our results indicate that CD40 expression is increased upon activation with antigen/MHC and that activation of NOD CD4 T cells through TCR/CD40 rapidly induced CD40 expression. Furthermore, CD40 costimulation promoted T cell proliferation to the same extent as costimulation through TCR/CD28. Importantly, costimulation of CD4 T cells through CD40 also interfered with T cell homeostasis by altering regulation of CTLA-4 expression. Through CD40-CD154 blocking studies, we demonstrated that signaling between T cells through CD40 and its ligand contributes to activation of pathogenic T cells and that blocking CD40 on T cells abrogates their ability to transfer diabetes. Thus, costimulation through CD40 on NOD T cells contributes to their pathogenicity by providing additional pathways for activation and by inhibiting upregulation of CTLA-4 during T cell activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18951762     DOI: 10.1016/j.jaut.2008.09.001

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  32 in total

1.  CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity.

Authors:  Gisela M Vaitaitis; David H Wagner
Journal:  Mol Immunol       Date:  2010-06-19       Impact factor: 4.407

2.  The co-evolution of our understanding of CD40 and inflammation.

Authors:  D H Wagner
Journal:  Diabetologia       Date:  2009-04-10       Impact factor: 10.122

3.  Anti-factor VIII antibodies (Inhibitors) in hemophilia A: in dire need of basic and therapeutic research.

Authors:  Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 4.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 5.  Of the multiple mechanisms leading to type 1 diabetes, T cell receptor revision may play a prominent role (is type 1 diabetes more than a single disease?).

Authors:  D H Wagner
Journal:  Clin Exp Immunol       Date:  2016-07-25       Impact factor: 4.330

6.  A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis.

Authors:  Gisela M Vaitaitis; Martin G Yussman; David H Wagner
Journal:  J Neuroimmunol       Date:  2019-03-21       Impact factor: 3.478

Review 7.  Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance.

Authors:  Tijana Martinov; Brian T Fife
Journal:  Ann N Y Acad Sci       Date:  2019-04-26       Impact factor: 5.691

Review 8.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

Review 9.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  Elimination of T cell reactivity to pancreatic β cells and partial preservation of β cell activity by peptide blockade of LFA-1:ICAM-1 interaction in the NOD mouse model.

Authors:  Abby L Dotson; Lesya Novikova; Lisa Stehno-Bittel; Stephen H Benedict
Journal:  Clin Immunol       Date:  2013-05-09       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.